Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

1 paper

Ayahuasca for Anxiety

Based on 13 papers

Research on ayahuasca for anxiety is small but shows some promising signs. A few clinical studies — including one trial that tested ayahuasca — reported lower anxiety after treatment, and many reviews say psychedelic treatments can help anxiety in some people. However, most studies are small, vary a lot in how they are done, and often include mostly White participants, so we cannot be sure the findings apply to everyone (15068, 15082, 15085, 15095). Scientists have ideas about how ayahuasca might work. Its active chemical, DMT, acts on serotonin-linked brain systems and lab and animal studies show it can change brain connections. But human brain markers are harder to measure, and one big review found no clear change in a common blood marker (BDNF) after psychedelic drugs, so the exact brain changes in people are still uncertain (15082, 15050, 15091, 15129). Overall, more large, careful trials and better safety data are needed before strong conclusions can be made (15068, 15085).

Key findings

  • A small number of clinical studies found that psychedelic treatments reduced anxiety symptoms, and one trial specifically tested ayahuasca and reported lower anxiety afterward. 15068
  • Many reviews say psychedelic medicines, including ayahuasca, give promising results for mood and anxiety problems, but the evidence is still early and limited. 15058 15085 15082
  • DMT, the main active compound in ayahuasca, mainly works on serotonin-related brain receptors and can help the brain form new connections in lab and animal studies. 15082 15050 15059
  • Human studies that measure a blood protein called BDNF (a marker people sometimes use to guess at brain change) did not show clear rises after giving psychoplastogen drugs, which includes some psychedelics. 15129
  • The treatment setting, preparation, and follow-up therapy matter a lot; many patients say trust, safety, the therapist, and music shape whether the experience helps them. 15092 15063 15087
  • Some animal studies show that effects can depend on dose and sex, and high doses of related compounds have caused harm in animals, so safety is not fully known. 15050 15085
  • Clinical trials so far are small and often short. Some report benefits that last for weeks, but bigger and longer studies are needed to know how long help lasts and who benefits most. 15068 15063 15085
  • People of color were greatly underrepresented in many older psychedelic psychotherapy studies, so findings may not apply well across different ethnic and cultural groups. 15095

Effects of Psychedelics in Older Adults: A Prospective Cohort Study

Hannes Kettner, Leor Roseman, Adam Gazzaley, Robin Carhart‐Harris, Lorenzo Pasquini

Researchers followed 62 older adults (age 60 and up) and 62 younger adults who planned to take part in guided psychedelic group sessions. People in both age groups reported better well-being in the weeks after the sessions, but older adults experienced weaker immediate drug effects during the sessions. For older…

Biochemical Analysis and Sensing Techniques Chemical synthesis and alkaloids Psychedelics and Drug Studies Ayahuasca LSD
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.